deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04777045

Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial (EDIT-CMD)

Sponsor: Radboud University Medical Center

Updated 5 times since 2021 Last updated: Mar 29, 2023 Started: Oct 25, 2019 Primary completion: Jul 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Coronary Vasospasm and Microvascular Angina, this trial is ongoing. The trial is conducted by Radboud University Medical Center and has accumulated 5 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Apr 2021 – ~Mar 2022 · 11 months · monthly snapshotRecruiting~Mar 2022 – ~Apr 2023 · 13 months · monthly snapshotRecruiting~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotActive Not Recruiting

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  4. Mar 2022 — Apr 2023 [monthly]

    Recruiting PHASE3

  5. Apr 2021 — Mar 2022 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Radboud University Medical Center
Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .